News | November 22, 2022
Natural Biogenex completes its maiden fund-raise of Rs 18.75 Cr
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Subscribe To Our Newsletter & Stay Updated
